Acrux Ltd
Acrux Limited is an Australia-based specialty pharmaceutical company.
The business
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Small Caps Research
No research on Acrux Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise ACR based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Acrux and TruPharma launch generic acne treatment in US market
Specialty pharmaceutical company Acrux (ASX: ACR) and its partner TruPharma have launched a generic version of Aczone 5% Gel on the US market to treat acne vulgaris. Known as Dapsone 5% Gel, the prescription topical medicine was created to manage the common skin condition that involves blockage and inflammation of hair follicles and accompanying sebaceous […]
FDA approval paves way for Acrux to launch generic testosterone topical solution in US
Pharmaceutical company Acrux (ASX: ACR) has secured United Stated Food and Drug Administration approval for its generic testosterone topical solution. The topical drug is based on Perrigo’s Testosterone Topical solution which has a dose of 30mg per 1.5mL. Acrux initially submitted an abbreviated new drug application with the FDA in August 2018 to market its […]
ASX-listed pooled development funds offer investors tax benefits
Astute investors weigh up the pros and cons before putting their hard earned money behind a company, and what appeals to people who invest in pooled development funds (PDFs) is the availability of generous tax concessions. PDFs raise capital and make equity investments in small and medium-sized (SMEs) enterprises after complying with a structure established […]
FDA accepts Acrux application for generic version of nail fungus drug Jublia
Pharmaceutical company Acrux (ASX: ACR) is a step closer to commercialising a topical treatment for onychomycosis in the US after this morning’s news that the US Food and Drug Administration (FDA) had accepted Acrux’ “Paragraph IV Abbreviated” new drug application (ANDA) dossier. The acceptance means the Acrux product will be reviewed for approval by the […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.